专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO0110893A3 IL-16 ANTAGONISTS 审中-公开
标题翻译： IL-16拮抗剂
公开(公告)号：WO0110893A3
公开(公告)日：2001-08-16
申请号：PCT/US0021317
申请日：2000-08-04
申请人： RES CORP TECHNOLOGIES INC
发明人： CENTER DAVID M , CRUIKSHANK WILLIAM W , KORNFELD HARDY
IPC分类号： C12N15/09 , A61K31/56 , A61K38/00 , A61K39/395 , A61P1/04 , A61P5/14 , A61P11/06 , A61P25/00 , A61P29/00 , A61P31/22 , C07K5/10 , C07K5/11 , C07K7/06 , C07K7/08 , C07K14/54 , C07K16/44 , A61K38/20 , C07K16/24 , C12N15/24
CPC分类号： A61K38/13 , A61K31/00 , A61K38/00 , A61K39/395 , A61K45/06 , C07K14/5446 , A61K2300/00
摘要： The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated that such IL-16-inhibiting peptides can be as short as 4 amino acid in length. Based on these discoveries, the present invention provides IL-16 antagonist peptides and the use thereof for the treatment of IL-16 mediated disorders such as certain inflammatory diseases.
摘要翻译：本发明已经发现，具有基本上对应于IL-16的C末端的特定区域的序列的一系列肽可以抑制IL-16的活性。本发明已经证明，这种IL-16抑制肽的长度可以短至4个氨基酸。基于这些发现，本发明提供IL-16拮抗剂肽及其用于治疗IL-16介导的病症例如某些炎性疾病的用途。

2. 发明申请

WO0110891A3 IL-16 ANTAGONISTS 审中-公开
标题翻译： IL-16拮抗剂
公开(公告)号：WO0110891A3
公开(公告)日：2001-08-16
申请号：PCT/US0021228
申请日：2000-08-04
申请人： RES CORP TECHNOLOGIES INC
发明人： CRUICKSHANK WILLIAM W , KORNFELD HARRY , CENTER DAVID M
IPC分类号： A61K38/00 , A61K38/08 , C07K5/103 , C07K7/06 , C07K14/73 , C07K14/705 , A61K38/17 , A61P29/00 , C07K16/28 , C12N15/13
CPC分类号： C07K7/06 , A61K38/00 , C07K5/1013 , C07K14/70514
摘要： In accordance with the present invention, novel IL-16 antagonists, preferably peptides derived from CD4, have been isolated and synthesized. These peptides possess IL-16 antagonistic properties including the ability to selectively bind to IL-16 and inhibit IL-16-mediated biological activity. The peptides comprise specific portions of the native human CD4 receptor and variations thereof and therefore are non-immunogenic when administered to humans. The present invention also provides compositions containing at least one IL-16 antagonist peptide which can inhibit, suppress or cause the cessation of at least one IL-16-mediated biological activity in mammals, including humans. The present invention provides a method and composition for treating inflammation associated with disease states such as asthma, rheumatoid arthritis, inflammatory bowel disease (IBD) and systemic lupus (SLE) in mammals such as, for example, humans.
摘要翻译：根据本发明，已经分离并合成了新的IL-16拮抗剂，优选来源于CD4的肽。这些肽具有IL-16拮抗特性，包括选择性结合IL-16和抑制IL-16介导的生物学活性的能力。肽包含天然人CD4受体的特定部分及其变体，因此当给予人时是非免疫原性的。本发明还提供了包含至少一种IL-16拮抗剂肽的组合物，其可抑制，抑制或引起哺乳动物（包括人）中至少一种IL-16介导的生物学活性的停止。本发明提供了用于在哺乳动物例如人中治疗与疾病状态相关的炎症例如哮喘，类风湿性关节炎，炎性肠病（IBD）和系统性红斑狼疮（SLE）的方法和组合物。

3. 发明专利

MXPA02001268A ANTAGONISTAS DE IL-16. 未知
公开(公告)号：MXPA02001268A
公开(公告)日：2003-09-10
申请号：MXPA02001268
申请日：2000-08-04
申请人： RES CORP TECHNOLOGIES INC
发明人： CENTER DAVID M
IPC分类号： A61K31/56 , C12N15/09 , A61K38/00 , A61K39/395 , A61P1/04 , A61P5/14 , A61P11/06 , A61P25/00 , A61P29/00 , A61P31/22 , C07K5/10 , C07K5/11 , C07K7/06 , C07K7/08 , C07K14/54 , C07K16/44 , C07K4/00

4. 发明专利

ES2205037T3 未知
公开(公告)号：ES2205037T3
公开(公告)日：2004-05-01
申请号：ES96918305
申请日：1996-06-07
申请人： RES CORP TECHNOLOGIES INC
发明人： CENTER DAVID M , CRUIKSHANK WILLIAM W , KORNFELD HARDY
IPC分类号： A61K38/00 , A61K38/20 , C07K14/54 , C07K16/22 , C07K16/24 , A61K39/395 , G01N33/577 , G01N33/68
摘要： Disclosed is a substantially pure antibody which specifically binds a LCF polypeptide and methods of using such antibodies.

5. 发明专利

CA2223262A1 LYMPHOCYTE CHEMOATTRACTANT FACTOR AND USES THEREOF 未知
公开(公告)号：CA2223262A1
公开(公告)日：1996-12-19
申请号：CA2223262
申请日：1996-06-07
申请人： RES CORP TECHNOLOGIES INC
发明人： CRUIKSHANK WILLIAM W , KORNFELD HARDLY , CENTER DAVID M
IPC分类号： A61K38/00 , A61K38/20 , C07K14/54 , C07K16/22 , C07K16/24 , C12N5/08 , A61K35/14 , A61K39/395 , G01N33/53
摘要： Disclosed is a substantially pure antibody which specifically binds an LCF polypeptide and methods of using such antibodies.

6. 发明专利

CA2378778C IL-16 ANTAGONISTS 未知
公开(公告)号：CA2378778C
公开(公告)日：2011-04-19
申请号：CA2378778
申请日：2000-08-04
申请人： RES CORP TECHNOLOGIES INC
发明人： CENTER DAVID M , CRUIKSHANK WILLIAM W , KORNFELD HARDY
IPC分类号： C12N15/09 , C12N15/24 , A61K31/56 , A61K38/00 , A61K38/20 , A61K39/395 , A61P1/04 , A61P5/14 , A61P11/06 , A61P25/00 , A61P29/00 , A61P31/22 , C07K5/10 , C07K5/11 , C07K7/06 , C07K7/08 , C07K14/54 , C07K16/24 , C07K16/44
摘要： The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated that such IL-16-inhibiting peptides can be as short as 4 amino acid in length. Based on these discoveries, the present invention provides IL-16 antagonist peptides and the use thereof for the treatment of IL-16 mediated disorders such as certain inflammatory diseases.

7. 发明专利

AT248190T 未知
公开(公告)号：AT248190T
公开(公告)日：2003-09-15
申请号：AT96918305
申请日：1996-06-07
申请人： RES CORP TECHNOLOGIES INC
发明人： CENTER DAVID M , CRUIKSHANK WILLIAM W , KORNFELD HARDY
IPC分类号： A61K38/00 , A61K38/20 , C07K14/54 , C07K16/22 , C07K16/24 , A61K39/395 , G01N33/577 , G01N33/68
摘要： Disclosed is a substantially pure antibody which specifically binds a LCF polypeptide and methods of using such antibodies.

8. 发明专利

CA2378778A1 IL-16 ANTAGONISTS 未知
公开(公告)号：CA2378778A1
公开(公告)日：2001-02-15
申请号：CA2378778
申请日：2000-08-04
申请人： RES CORP TECHNOLOGIES INC
发明人： CRUIKSHANK WILLIAM W , KORNFELD HARDY , CENTER DAVID M
IPC分类号： C12N15/09 , A61K31/56 , A61K38/00 , A61K39/395 , A61P1/04 , A61P5/14 , A61P11/06 , A61P25/00 , A61P29/00 , A61P31/22 , C07K5/10 , C07K5/11 , C07K7/06 , C07K7/08 , C07K14/54 , C07K16/44 , C12N15/24 , A61K38/20 , C07K16/24
摘要： The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated th at such IL-16-inhibiting peptides can be as short as 4 amino acid in length. Based on these discoveries, the present invention provides IL-16 antagonist peptides and the use thereof for the treatment of IL-16 mediated disorders such as certain inflammatory diseases.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式